跳至主要内容
临床试验/CTRI/2024/07/071087
CTRI/2024/07/071087尚未招募4 期

A Comparitive study of Dapagliflozin Vs Pioglitazone in Patients of Non Alcoholic Fatty liver disease with Type 2 Diabetes Mellitus

Babra1 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2024年8月1日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
108
试验地点
1
主要终点
Achieving the target level of HbA1C 6.5%

研究概览

简要总结

TITLE: A COMPARATIVE STUDY OF  DAPAGLIFLOZIN VS PIOGLITAZONE IN PATIENTS OF NON ALCOHOLIC FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS BACKGROUND: NAFLD Is a condition in which excess fat builds up in the liver.This buildup of fat is not caused by heavy alcohol use. DAPAGLIFLOZIN An inhibitor of sodium-glucose co-transporter 2 (SGLT2),decreases blood glucose levels without the use of insulin by improving renal glucose excretion. PIOGLITAZONE Is an oral drug It works by stimulating nuclear receptors known as peroxisome proliferator-activated receptor gamma(PPAR-γ) and modifies gene expression through binding to PPAR-γ, which has several consequences. MATERIAL AND METHODS: The study employed a prospective, randomized, open-label design and was conducted at ERA’S Lucknow Medical College & Hospital, with collaboration from the Department of Pharmacology, Medicine, and Radiology. It involved a total sample size of 108 patients, evenly distributed with 54 patients in each group. The study continued for a duration of 18 months

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 1 NAFLD Fibrosis Score(Stage 1 to Stage 3) 2 USG (Grade 2 & Grade 3 fatty liver) 3 HbA1C 6.5% & above 4 BMI 23 kg/m² & above 5 Type 2 diabetes mellitus patient on treatment of metformin (upto 2g/day).

排除标准

  • 1 Patient with heart failure, kidney failure, malignancy 2 Pregnant & Lactating mothers 3 Habitual drinkers 4 Contraindication to dapagliflozin and pioglitazone 5 Use of steroid &/ or other immunosuppressor 6 H/o mental illness or inability to co operate.

结局指标

主要结局

Achieving the target level of HbA1C 6.5%

时间窗: 3 week 6 week 12 week

次要结局

  • Secondary Outcome:(• Assessment of glycemic control (HbA1c) in participants.)

研究者

发起方
Babra
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Babra

Eras Lucknow Medical College

研究点 (1)

Loading locations...

相似试验